Production chemotherapy with versus without hormonal synchronisation in locally advanced breast cancer

Acta Oncologica

Volumn 36, Issue 2, 1997, Pages 207-212

  Sjövall, Margareta Palm ^a   Malmström, Per ^a  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; ESTROGEN RECEPTOR; FLUOROURACIL; METHOTREXATE; TAMOXIFEN; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; ESTROGEN;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BREAST CANCER; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HORMONAL THERAPY; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; BREAST TUMOR; CELL CYCLE G1 PHASE; CELL DIVISION; DISEASE COURSE; DRUG EFFECT; MIDDLE AGED; NEOPLASM; PATHOLOGY; REMISSION;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, HORMONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CELL DIVISION; DISEASE PROGRESSION; ESTROGENS; FEMALE; FLUOROURACIL; G1 PHASE; HUMANS; METHOTREXATE; MIDDLE AGED; NEOPLASMS, HORMONE-DEPENDENT; REMISSION INDUCTION; TAMOXIFEN;

EID: 0030612261     PISSN: 0284186X     EISSN: None     Source Type: Journal    
DOI: 10.3109/02841869709109231     Document Type: Article

References (27)

1. Haagensen CD, Stout AP. Carcinoma of the breast; criteria of operability. Annals Surg 1943; 118: 859-70, 1032-51.
2. Montague ED, Fletcher GH. Local regional effectiveness of surgery and radiation therapy in the treatment of breast cancer. Cancer 1985; 55: 2266-72.
3. Bedwinek J, Rao DV, Perez C, Lee J, Fineberg B. Stage III and localized stage IV breast cancer: irradiation alone vs irradiation plus surgery. Int J Radiat Oncol Biol Phys 1982; 8: 31-6.
4. Balawajder I, Antich PP, Boland J. An analysis of the role of radiotherapy alone and in combination with chemotherapy and surgery in management of advanced breast carcinoma. Cancer 1983; 51: 574-80
5. Hortobagyi GN, Ames FC, Buzdar AU. Management of Stage III primary breast cancer with primary chemotherapy, surgery and radiation therapy. Cancer 1988; 62: 2507-16.
6. Rubens RD, Bartelink H, Engelsman JL, et al. Locally advanced breast cancer: the contribution of cytotoxic and endocrine treatment to radiotherapy. Eur J Cancer Clin Oncol 1989; 25: 667-78.
7. Perloff M, Lesnick GJ, Korzun A. Combination chemotherapy with mastectomy or radiotherapy for stage III breast carcinoma: a cancer and leukemia group B study. J Clin Oncol 1988; 6: 261-9.
8. Touboul E, Lefranc J-P, Blondon J. Multidisciplinary treatment approach to locally advanced non-inflammatory breast cancer using chemotherapy and radiotherapy with or without surgery. Radiotherpy and Oncology 1992; 25: 167-75.
9. Vlagussa P, Zambetti M, Bonnadonna G, Zucali R, Mezzanotte G, Veronesi, U. Prognostic factors in locally advanced non-inflammatory breast cancer. Long-term results following primary chemotherapy. Breast Cancer Res Treat 1990; 15: 137-47.
10. Lippman ME, Cassidy J, Wesley M, Young RC. A randomized attempt to increase the efficacy of cytotoxic chemotherapy in metastatic breast cancer by hormonal synchronization. J Clin Oncol 1984 2: 28-36.
11. Lippman ME, Sorace RA, Bagley CS, Danforth DW, Lichter A, Wesley M. Treatment of locally advanced breast cancer using primary induction chemotherapy with hormonal synchronization followed by radiation therapy with or without debulking surgery. NCI Monogr 1986; 1: 153-9
12. Swain SM, Sorace RA, Bagley CS. Neoadjuvant chemotherapy in the combined modality approach of locally advanced nonmetastatic breast cancer. Cancer Res 1987; 47: 3889-94.
13. Pierce LJ, Lippman ME, Ben-Baruch N, et al. The effect of systemic therapy on local-regional control in locally advanced breast cancer. Int J Radiat Oncol Biol Phys 1992; 23: 949-60.
14. Lippman ME, Bolan G, Huff K. The effects of estrogen and antiestrogens on hormone-responsive human breast cancer in long-term tissue culture. Cancer Res 1976; 36: 4595-601.
15. Weichselbaum RR, Hellman S, Piro AJ et al. Proliferation kinetics of a human breast cancer cell line in vitro following treatment with 17b estradiol and 1 b-D arabinofuranosylcytosine. Cancer Res 1978; 38: 2339-45.
16. Bontenbal AM, Siuwertz JGM, Klijn HA, et al. Effect of hormonal manipulation and doxorubicin administration on cell cycle kinetics of human breast cancer cells. Br J Cancer 1989; 60: 688-92.
17. Hermanek, P, Sobin, LH, UICC, TNM classification of malignant tumors. Springer-Verlag, 1987.
18. Borg Å, Fernö M, Idvall I. Estrogen receptor enzyme immunoassay in fine-needle aspirates from human breast cancer. Acta Oncol 1989; 28: 187-91.
19. McGuire WL, Osborne CK, Clark GM, Knight WA. Steroid receptors and carcinoma of the breast. Am J Physiol 1982; 243: E99-E102.
20. McGuire WL. An update on estrogen and progesterone receptors in prognosis for primary and advanced breast cancer. In: Jacobelli S et al., eds. Hormones and cancer. New York: Raven Press, 1980: 337-43.
21. Fernö M, Borg Å, Johansson U, et al. Estrogen and progesterone receptor analyses in more than 4000 human breast cancer samples. Acta Oncol 1990; 29: 129-35.
22. Hayward JL, Carbone PP, Heuson J-C, Kumaoka S, Segaloff A, Rubens RD. Assessment of response to therapy in advanced breast cancer. Cancer 1977; 39: 1289-93.
23. WHO handbook for reporting results of cancer treatment. WHO offset publication nr 48 Geneva, 1979.
24. Lipton A, Santen RJ, Harvey HA, et al. A randomized trial of aminoglutethimide ± estrogen before chemotherapy in advanced cancer. Am J Clin Oncol. (CCT) 1987; 10: 65-70.
25. Conte PF, Pronzato P, Rubagotti A, et al. Conventional versus cytokinetic polychemotherapy with estrogenic recruitment in metastatic breast cancer: results of a randomized cooperative trial. J Clin Oncol 1987; 5: 339-47.
26. Kamby C, Bruun Rasmussen B, Kristensen B. Oestrogen receptor status of primary breast carcinomas and their metastases. Relation to pattern of spread and survival after recurrence. Br J Cancer 1989; 60: 252-7.
27. Kuukasjärvi T, Kononen J, Helin H, Holli K, Isola J. Loss of estrogen receptor in recurrent breast Cancer is associated with poor response to endocrine therapy. J Clin Oncol 1996; 14: 2584-9.